Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)
Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM) J2556
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
35 participants
May 26, 2026
INTERVENTIONAL
Conditions
Summary
The Brain Cancer Program, in partnership with the Center for Music and Medicine at Johns Hopkins, will study whether music therapy is feasible in newly diagnosed GBM patients undergoing standard care.
Eligibility
Inclusion Criteria6
- Glioblastoma
- Cognitive capacity to respond to surveys
- Access to computer and web access
- Ability to attend virtual music therapy sessions
- Audibly process music
- Proficient in English
Exclusion Criteria4
- Not planning to undergo standard of care radiation therapy and concurrent and adjuvant temozolomide.
- A life expectancy of less than 6 months.
- Concurrent use of any other standard or investigational agents (excepting tumor treating fields).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit adherence with study requirements.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Each GBM study participant in Arm A will receive two 30-minute live synchronous virtual music therapy sessions per week for a period of 8 weeks to be curated by a board-certified music therapist. Arm B participants will receive curated playlists of music created by a music therapist. Participants will then listen to the curated music playlists on the participant's own device twice per week. All participants will complete a total of 16 music therapy sessions, scheduled twice per week over 8 weeks. Each session will last approximately 30 minutes.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07375992